

UTILIZATION MANAGEMENT MEDICAL POLICY

- POLICY:** Colony Stimulating Factors – Filgrastim Products Utilization Management Medical Policy
- Neupogen® (filgrastim intravenous or subcutaneous injection – Amgen)
 - Nivestym® (filgrastim intravenous or subcutaneous injection – Pfizer)
 - Nypozi™ (filgrastim-txid intravenous or subcutaneous injection – Apotex)
 - Releuko® (filgrastim-ayow intravenous or subcutaneous injection – Amneal)
 - Zarxio® (filgrastim-sndz intravenous or subcutaneous injection – Sandoz)

REVIEW DATE: 10/22/2025

OVERVIEW

Filgrastim, a granulocyte colony stimulating factor (G-CSF), is indicated for the following uses:¹⁻⁵

- **Decrease the incidence of infection, as manifested by febrile neutropenia**, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
- **Mobilization of hematopoietic progenitor cells**, into the peripheral blood for collection by leukapheresis.
- **Reduce the time to neutrophil recovery and the duration of fever**, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia (AML).
- **Reduce the duration of neutropenia and neutropenia-related clinical sequelae** (e.g., febrile neutropenia), in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).
- **Reduce the incidence and duration of sequelae of neutropenia** (e.g., fever, infections, oropharyngeal ulcers), in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.
- **Increase survival in patients acutely exposed to myelosuppressive doses of radiation** (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])

Nivestym, Nypozi, Releuko, and Zarxio are FDA-approved biosimilars to Neupogen.¹⁻⁵

Guidelines

The National Comprehensive Cancer Network (NCCN) addresses the use of filgrastim products in several guidelines. Of note, throughout the recommendations, it is acknowledged that an FDA-approved biosimilar is an appropriate substitute for filgrastim.

- **Acute Lymphoblastic Leukemia (ALL):** Guidelines (version 2.2024 – June 27, 2025) recommend G-CSFs as supportive care for myelosuppressive blocks of therapy or as directed by treatment protocol.⁶
- **Acute Myeloid Leukemia (AML):** Guidelines (version 2.2026 – October 2, 2025) recommend G-CSFs as supportive care for myelosuppressive blocks of therapy or as directed by treatment protocol.¹¹
- **Hematopoietic Cell Transplantation:** Guidelines (version 3.2025 – September 24, 2025) recommend filgrastim for hematopoietic cell mobilization for allogeneic or autologous donors as a single agent or in combination with other treatments.⁷
- **Hematopoietic Growth Factors:** Guidelines (version 1.2025 – October 11, 2024) recommend filgrastim, along with other CSFs, for prophylactic use if the patient is receiving anti-cancer medications that are associated with a high (> 20%) incidence of severe neutropenia with fever.⁸ Consider CSF therapy for patients with an intermediate (10% to 20%) probability of developing

10/22/2025

© 2025. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

febrile neutropenia based on risk factors. The NCCN guidelines also recommend therapy with CSFs in other scenarios in those given myelosuppressive chemotherapy. Filgrastim is also recommended as an appropriate option for the treatment of patients with radiation-induced myelosuppression following a radiologic/nuclear incident (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

- **Management of Immunotherapy-Related Toxicities:** Guidelines (version 1.2025 – December 20, 2024) recommend consideration of G-CSFs as supportive care for neutropenic patients resulting from chimeric antigen receptor T-cell therapy.⁹
- **Myelodysplastic Syndromes (MDS):** Guidelines (version 1.2026 – October 9, 2025) consider filgrastim for use in certain patients (e.g., neutropenic patients with recurrent or resistant infections, combination use with epoetin alfa or Aranesp® [darbepoetin alfa injection] in patients with anemia).¹⁰

Other Uses with Supportive Evidence

Neutropenia occurs in patients with human immunodeficiency virus (HIV) and may be caused by medications or due to the disease process. Studies have demonstrated positive outcomes with the use of filgrastim for the treatment of neutropenia in this patient population.¹²⁻¹⁵

Filgrastim has been used for agranulocytosis caused by non-cytotoxic medications, primarily described in case series, case reports and literature reviews.¹⁶⁻²²

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of filgrastim products. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with filgrastim as well as the monitoring required for adverse events and long-term efficacy, approval for some conditions requires filgrastim to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of filgrastim products is recommended in those who meet one of the following:

FDA-Approved Indications

-
1. **Acute Myeloid Leukemia (AML) in a Patient Receiving Chemotherapy.** Approve for 6 months if prescribed by or in consultation with an oncologist or hematologist.

Dosing. Approve up to 10 mcg/kg per day by intravenous or subcutaneous injection.

-
2. **Bone Marrow Transplant (BMT) in a Patient with Cancer Who Received Chemotherapy.** Approve for 1 month if prescribed by or in consultation with a hematologist, an oncologist, or a physician who specializes in transplantation.

Dosing. Approve up to 30 mcg/kg per day by intravenous or subcutaneous injection.

3. Cancer in a Patient Receiving Myelosuppressive Chemotherapy. Approve for 6 months if the patient meets BOTH of the following (A and B):

A) Patient meets ONE of the following (i, ii, iii, or iv):

i. Patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen); OR

ii. Patient meets BOTH of the following (a and b):

a) Patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia, but the risk is less than 20% based on the chemotherapy regimen; AND

b) Patient has at least one risk factor for febrile neutropenia according to the prescriber; OR
Note: Examples of risk factors include age > 65 years of age receiving full chemotherapy dose intensity; prior chemotherapy or radiation therapy; persistent neutropenia; bone marrow involvement by tumor; recent surgery and/or open wounds; liver dysfunction (bilirubin > 2.0 mg/dL); renal dysfunction (creatinine clearance < 50 mL/min); poor performance status; patient with human immunodeficiency virus (HIV) infection and low CD4 counts.

iii. Patient meets BOTH of the following (a and b):

a) Patient has had a neutropenic complication from a prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor; AND

Note: Examples of colony stimulating factors include filgrastim products, pegfilgrastim products, Ryzneuta (efbmalenograftim alfa-vuxw subcutaneous injection), Rolvedon (eflapegraftim-xnst subcutaneous injection).

b) A reduced dose or frequency of chemotherapy may compromise treatment outcome; OR

iv. Patient who has received chemotherapy has febrile neutropenia AND has at least one risk factor for poor clinical outcomes or for developing infection-associated complications according to the prescriber; AND

Note: Examples of risk factors include sepsis syndrome; age > 65 years; severe neutropenia (absolute neutrophil count [ANC] < 100 cells/mm³); neutropenia expected to be > 10 days in duration; pneumonia or other clinically documented infections; invasive fungal infection; hospitalization at the time of fever; prior episode of febrile neutropenia.

B) The medication is prescribed by or in consultation with an oncologist or hematologist.

Dosing. Approve up to 10 mcg/kg per day by intravenous or subcutaneous injection for up to 14 days per month.

4. Peripheral Blood Progenitor Cell (PBPC) Collection and Therapy. Approve for 1 month if prescribed by or in consultation with an oncologist, a hematologist, or a physician who specializes in transplantation.

Dosing. Approve up to 10 mcg/kg per day by intravenous or subcutaneous injection.

5. Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). Approve for 1 month if prescribed by or in consultation with a physician who has expertise in treating acute radiation syndrome.

Dosing. Approve up to 10 mcg/kg per day as a subcutaneous injection.

-
- 6. Severe Chronic Neutropenia (e.g., Congenital Neutropenia, Cyclic Neutropenia, Idiopathic Neutropenia).** Approve for 6 months if prescribed by or in consultation with a hematologist.

Dosing. Approve up to 12 mcg/kg per day by subcutaneous injection.

Other Uses with Supportive Evidence

-
- 7. Acute Lymphoblastic Leukemia (ALL) in a Patient Receiving Chemotherapy.** Approve for 1 month if prescribed by or in consultation with an oncologist or a hematologist.

Dosing. Approve up to 10 mcg/kg per day by intravenous or subcutaneous injection.

-
- 8. Immunotherapy-Related Toxicities Associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy.** Approve for 1 month if prescribed for a patient who has neutropenia.

Note: Examples of CAR T-cell therapy include Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).

Dosing. Approve up to 10 mcg/kg per day by intravenous or subcutaneous injection.

-
- 9. Drug-Induced (Non-Chemotherapy) Agranulocytosis or Neutropenia.** Approve for 1 month.

Dosing. Approve up to 10 mcg/kg per day as a subcutaneous injection.

-
- 10. Myelodysplastic Syndromes (MDS).** Approve for 3 months if prescribed by or in consultation with an oncologist or hematologist.

Dosing. Approve up to 5 mcg/kg per day by intravenous or subcutaneous injection.

-
- 11. Neutropenia Associated with Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS).** Approve for 4 months if the agent is prescribed by or in consultation with a physician that specializes in infectious diseases, a hematologist, or a physician who specializes in the management of HIV/AIDS.

Dosing. Approve up to 10 mcg/kg per day as a subcutaneous injection.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of filgrastim products is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Neupogen® subcutaneous or intravenous injection [prescribing information]. Thousand Oaks, CA: Amgen; April 2023.
2. Zarxio® subcutaneous or intravenous injection [prescribing information]. Princeton, NJ: Sandoz; October 2024.
3. Nivestym® subcutaneous or intravenous injection [prescribing information]. Lake Forest, IL and New York, NY: Hospira and Pfizer; February 2024.
4. Releuko® subcutaneous or intravenous injection [prescribing information]. Bridgewater, NJ: Amneal; April 2025.
5. Nypozit™ subcutaneous or intravenous injection [prescribing information]. San Diego, CA: Tanvex, June 2024.
6. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 2.2025 – June 27, 2025). © 2025 National Comprehensive Cancer Network. Available at <http://www.nccn.org>. Accessed on October 16, 2025.
7. The NCCN Hematopoietic Cell Transplantation Clinical Practice Guidelines in Oncology (version 3.2025 – September 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 7, 2025.
8. The NCCN Hematopoietic Growth Factors Clinical Practice Guidelines in Oncology (version 1.2025 – October 11, 2024). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 7, 2025.
9. The NCCN Management of Immunotherapy-Related Toxicities Clinical Practice Guidelines in Oncology (version 1.2025 – December 20, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 16, 2025.
10. The NCCN Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology (version 1.2026 – October 9, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 16, 2025.
11. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 2.2026 – October 2, 2025). © 2025 National Comprehensive Cancer Network. Available at <http://www.nccn.org>. Accessed on October 16, 2025.
12. Kuritzkes DR, Parenti D, Ward DJ, et al, and the G-CSF 930101 study group. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter controlled trial. *AIDS*. 1998;12:65-71.
13. Hermans P, Rozenbaum W, Joy A, et al, and the G-CSF 92105 Study Group. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. *AIDS*. 1996;10:1627-1633.
14. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor. *Clin Infect Dis*. 2000;30:256-260.
15. Mitsuyasu R. Prevention of bacterial infections in patients with advanced HIV infection. *AIDS*. 1999;13(Suppl 2):S19-S23.
16. Tesfa D, Keisu M, Palblad J. Idiosyncratic drug-induced agranulocytosis: Possible mechanism and management. *Am J Hematol*. 2009;84:428-434.
17. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. *Ann Intern Med*. 2007;146:657-665.
18. Beaushesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: A review of 118 patients treated with colony-stimulating factors. *Pharmacother*. 1999;19(3):299-305.
19. Bhatt V, Saleem A. Review: Drug-induced neutropenia-pathophysiology, clinical features, and management. *Ann Clin Lab Sci*. 2004;34(2):131-136.
20. Curtis BR. Drug-induced immune neutropenia/agranulocytosis. *Immunohematology*. 2014;30(2):95-101.
21. Andres E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia – an update. *Expert Opin Drug Saf*. 2017;16(11):1235-1242.
22. Andres E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. *QJM*. 2017 May;110(5):299-305.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Other Uses with Supportive Evidence: Radiation-Induced Neutropenia was removed from the policy.	09/20/2023
Annual Revision	<p>Cancer in a Patient Receiving Myelosuppressive Chemotherapy: The Note providing examples of risk factors for febrile neutropenia was updated from “≥ 65 years” to “> 65 years of age receiving full chemotherapy dose intensity”, liver dysfunction was defined as “bilirubin > 2.0 mg/dL”, renal dysfunction was defined as “creatinine clearance < 50 mL/min”, and human immunodeficiency infection patients was clarified by adding “with low CD4 counts.” The requirement for a patient to have had a neutropenic complication from “prior chemotherapy” was updated to add “cycle.” The Note providing examples of colony stimulating factors was updated to add Ryzneuta and Rolvedon and remove Leukine. The Note providing examples of risk factors associated with poor clinical outcomes for patients who have febrile neutropenia was updated to include pneumonia, hospitalization at the time of fever, and prior episode of febrile neutropenia.</p> <p>Peripheral Blood Progenitor Cell (PBPC) Collection and Therapy: The dosing limitation was lowered from 32 mcg/kg to 10 mcg/kg.</p> <p>Acute Lymphoblastic Leukemia (ALL) in a Patient Receiving Chemotherapy: The diagnosis was updated from “Acute Lymphoblastic Leukemia” to as listed. The dosing limitation was updated to add “or intravenous injection”.</p> <p>Cytokine Release Syndrome Associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: The Note providing examples of CAR T-Cell therapy was updated to add Abecma (idecabtagene vicleucel), Breynzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Tecartus (brexucabtagene autoleucel).</p>	10/09/2024
Update	Overview was updated to add Zarxio new indication to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).	11/04/2024
Selected Revision	Nypozi (filgrastim-txid intravenous or subcutaneous injection) was added to the Policy.	12/04/2024
Update	Overview: Overview was updated to reflect Releuko new indication for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis and new indication to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).	05/15/2025
Annual Revision	<p>Cancer in a Patient Receiving Myelosuppressive Chemotherapy: The Note was updated from “human immunodeficiency virus (HIV) infection patients with low CD4 counts” to “a patient with HIV infection and low CD4 counts.”</p> <p>Immunotherapy-Related Toxicities Associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: Diagnosis was updated from Cytokine Release Syndrome Associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy to as written.</p>	10/22/2025